NoGeneST™ Anti-VWF Aptamer, aVWF aptamer-5

Name: NoGeneST™ Anti-VWF Aptamer, aVWF aptamer-5
SKU: NRYF-0625-HZ67
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ67]

A modified RNA aptamer that inhibits the von Willebrand Factor (VWF) and platelet GPIb interaction, acting as an anti-thrombotic agent.

Target:: VWF

Type:: RNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is an engineered RNA aptamer designed to specifically target von Willebrand Factor (VWF). It functions by blocking the interaction between the A1 domain of VWF and the platelet glycoprotein receptor Ib (GPIb). This process is the critical initiating step for platelet adhesion and subsequent thrombus formation in arteries under high shear stress. By inhibiting this interaction, the aptamer shows potential as a potent anti-thrombotic therapy.

Type

RNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

VWF

Full Name

Von Willebrand Factor

Alternative Names

Factor VIII related antigen

Gene ID

7450

Uniprot ID

P04275

Target Overview

Von Willebrand Factor (VWF) is a large, multimeric glycoprotein that plays a central and critical role in hemostasis (the cessation of bleeding). It performs two primary functions in the bloodstream: first, it acts as a molecular bridge, mediating the adhesion of platelets to exposed subendothelial collagen at sites of vascular injury, a crucial initial step in forming a platelet plug. Second, it serves as a carrier protein for Coagulation Factor VIII, binding to it and protecting it from premature degradation in the circulation. The size and adhesive activity of VWF multimers are tightly regulated, and dysregulation of VWF function can lead to either bleeding disorders (like von Willebrand disease) or pathological thrombosis.

Publications